Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stevo Julius

Showing results (31-40 of 118) with videos related to

Pageof 12
Sort By:
American Journal of Hypertension|August 2, 2005
Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY studyShawna D Nesbitt, Stevo Julius, David Leonard, et al.
Biostatistics (Oxford, England)|January 7, 2012
A Bayesian model for time-to-event data with informative censoringNiko A Kaciroti, Trivellore E Raghunathan, Jeremy M G Taylor, et al.
Heart Rhythm|November 15, 2011
Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE studyPeter M Okin, Sverre E Kjeldsen, Stevo Julius, et al.
Journal of Hypertension|July 24, 2019
Consequences of the evolutionary cardiovascular challenge of human bipedalism: orthostatic intolerance syndromes, orthostatic hypertensionMurray Esler, Stevo Julius, Benjamin Coghlan, et al.
Journal of Hypertension|November 1, 2002
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular riskAlberto Zanchetti, Lennart Hansson, Björn Dahlöf, et al.
Journal of Hypertension|November 27, 2013
In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertensionStevo Julius, Brent M Egan, Niko A Kaciroti, et al.
Hypertension (Dallas, Tex. : 1979)|July 9, 2004
Trial of preventing hypertension: design and 2-year progress reportStevo Julius, Shawna Nesbitt, Brent Egan, et al.
Blood Pressure|January 26, 2016
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trialTonje A Aksnes, Sverre E Kjeldsen, Morten Rostrup, et al.
Hypertension (Dallas, Tex. : 1979)|August 8, 2007
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial populationTonje A Aksnes, Sverre E Kjeldsen, Morten Rostrup, et al.
Journal of Hypertension|February 28, 2008
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trialRoland E Schmieder, Sverre E Kjeldsen, Stevo Julius, et al.
Pageof 12

Showing results (31-40 of 118) with videos related to

Sort By:
Pageof 12
American Journal of Hypertension|August 2, 2005
Is low-risk hypertension fact or fiction? cardiovascular risk profile in the TROPHY studyShawna D Nesbitt, Stevo Julius, David Leonard, et al.
Biostatistics (Oxford, England)|January 7, 2012
A Bayesian model for time-to-event data with informative censoringNiko A Kaciroti, Trivellore E Raghunathan, Jeremy M G Taylor, et al.
Heart Rhythm|November 15, 2011
Racial differences in sudden cardiac death among hypertensive patients during antihypertensive therapy: the LIFE studyPeter M Okin, Sverre E Kjeldsen, Stevo Julius, et al.
Journal of Hypertension|July 24, 2019
Consequences of the evolutionary cardiovascular challenge of human bipedalism: orthostatic intolerance syndromes, orthostatic hypertensionMurray Esler, Stevo Julius, Benjamin Coghlan, et al.
Journal of Hypertension|November 1, 2002
Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular riskAlberto Zanchetti, Lennart Hansson, Björn Dahlöf, et al.
Journal of Hypertension|November 27, 2013
In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertensionStevo Julius, Brent M Egan, Niko A Kaciroti, et al.
Hypertension (Dallas, Tex. : 1979)|July 9, 2004
Trial of preventing hypertension: design and 2-year progress reportStevo Julius, Shawna Nesbitt, Brent Egan, et al.
Blood Pressure|January 26, 2016
Predictors of cardiac morbidity in diabetic, new-onset diabetic and non-diabetic high-risk hypertensive patients: The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trialTonje A Aksnes, Sverre E Kjeldsen, Morten Rostrup, et al.
Hypertension (Dallas, Tex. : 1979)|August 8, 2007
Impact of new-onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial populationTonje A Aksnes, Sverre E Kjeldsen, Morten Rostrup, et al.
Journal of Hypertension|February 28, 2008
Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trialRoland E Schmieder, Sverre E Kjeldsen, Stevo Julius, et al.
Pageof 12